Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / A Methylation Panel for Bladder Cancer

A Methylation Panel for Bladder Cancer

Gazdar, AdiUT Southwestern Medical Center

No involved investigator sites defined.

Prostate and Urologic Cancers Research Group

Participate in a prevalidation study for methylation based detection of bladder cancer. In addition, a panel of three markers identified will be evaluated for their ability to a) identify bladder cancer patients from those with benign urologic disease; b) identify patients with superficial (papillary) cancers from those with high grade invasive cancers

1) Participate in a prevalidation study for methylation based detection of bladder cancer. 2) Collect voided urine specimens from patients with a) invasive carcinomas, b) non-invasive carcinomas, and c) patients with urologic diseases who are free of cancer, including patients with hematuria 3) Test the panel of three methylation markers described in the Preliminary DAta for their ability to identify individuals with bladder cancer and to differentiate between invasive and non-invasive cancers

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.